Glenmark gets approval for antiretroviral trials, others also in dispute
MUMBAI: Despite Glenmark Pharma receiving regulatory approval to start clinical trials of the antiretroviral drug Favipiravir in Covid-19, other Mumbai-based companies are also preparing plans to manufacture the product to meet demand. These include API (Active Pharmaceutical Ingredient) manufacturer Lasa Supergenerics.
Favipiravir is an antiviral medication approved in Japan for the treatment of influenza and has shown promise as a potential treatment for coronavirus. The antimalarial drug hydroxychloroquine, or antiretroviral/antiviral drugs such as Favipiravir and Lopinavir, are increasingly being used worldwide for treatment. Glenmark received approval from the country's General Drug Controller to start clinical trials in May on 150 mild-to-moderate Covid-19 patients, the first of those firms, according to sources.
Additionally, Strides Pharma said it has developed and marketed Favipiravir tablets, a generic version of Avigan from Toyama Chemical, Japan. Strides is the first national company that has started the export of Favipiravir.